Coronary artery disease in women: From the yentl syndrome to contemporary treatment

Table 2 Women are considerably underrepresented in clinical trials[9]

Study	Sample MT.PCI	Enrollment n	Mean age (yr)	Male (%)	DM (%)	% Prior MI	1/2/3-Vessel CAD	% No symptoms	% Mean EF	% Follow up, yr
RITA-2	514/504	1992-1996	58 (Median)	82	9	47	60/33/7	20	ND1	7
ACME-1	115/112	1987-1990	60	100	18	31	100/0/0	9	68	2.4-52
ACME-2	50/51	1987-1990	60	100	18	41	0/100/0	18	67	2.4-52
AVERT	164/177	1995-1996	59	84	16	42	56/44/0	16	61	1.5
Dakik et al[58]	22/19	1995-1996	53	59	ND	100	44/41/15	0	46	1
MASS	72/72	1988-1991	56	58	18	0	100/0/0	0	76	5
MASS II	203/205	1995-2000	60	68	30	41	0/42/58	ND	67	1
ALKK	151/149	1994-1997	58	87	16	100	100/0/0	0	ND3	4.7
Sievers et al[59]	44/44	ND	56	ND	0	55	100/0/0	ND	ND	2
Hambrecht et al[60]	51/50	1997-2001	61	100	23	46	58/27/15	0	63	1
Bech et al[61]	91/90	ND	61	64	12	25	66/28/6	0	65	2

¹Ninety-three percent of patients had very good or excellent wall motion score;

²Ninety-seven percent of patients were in New York Heart Association class 1;

³Follow-up was 2.4 years (mean) to follow-up interview, 3 years (mean) to follow-up exercise test, and 5 years (median) for ascertainment of deaths and MI events. MT: Medical treatment; DM: Diabetes mellitus; EF: Ejection fraction; ND: No data available.